Brewer GJ - Search Results

1

Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma.

Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD. Pan Q, et al. Among authors: brewer gj. Mol Cancer Ther. 2003 Jul;2(7):617-22. Mol Cancer Ther. 2003. PMID: 12883034

2

Radiotherapy and antiangiogenic TM in lung cancer.

Khan MK, Miller MW, Taylor J, Gill NK, Dick RD, Van Golen K, Brewer GJ, Merajver SD. Khan MK, et al. Among authors: brewer gj. Neoplasia. 2002 Mar-Apr;4(2):164-70. doi: 10.1038/sj.neo.7900218. Neoplasia. 2002. PMID: 11896571 Free PMC article.

3

Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma.

van Golen KL, Bao L, Brewer GJ, Pienta KJ, Kamradt JM, Livant DL, Merajver SD. van Golen KL, et al. Among authors: brewer gj. Neoplasia. 2002 Sep-Oct;4(5):373-9. doi: 10.1038/sj.neo.7900258. Neoplasia. 2002. PMID: 12192595 Free PMC article.

4

Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.

Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ, Merajver SD. Pan Q, et al. Among authors: brewer gj. Cancer Res. 2002 Sep 1;62(17):4854-9. Cancer Res. 2002. PMID: 12208730

5

Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.

Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD. Redman BG, et al. Among authors: brewer gj. Clin Cancer Res. 2003 May;9(5):1666-72. Clin Cancer Res. 2003. PMID: 12738719 Clinical Trial.

6

Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model.

Cox C, Merajver SD, Yoo S, Dick RD, Brewer GJ, Lee JS, Teknos TN. Cox C, et al. Among authors: brewer gj. Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):781-5. doi: 10.1001/archotol.129.7.781. Arch Otolaryngol Head Neck Surg. 2003. PMID: 12874082

7

Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.

Brewer GJ, Merajver SD. Brewer GJ, et al. Integr Cancer Ther. 2002 Dec;1(4):327-37. doi: 10.1177/1534735402238185. Integr Cancer Ther. 2002. PMID: 14664727 Free article. Review.

8

Control of copper status for cancer therapy.

Goodman VL, Brewer GJ, Merajver SD. Goodman VL, et al. Among authors: brewer gj. Curr Cancer Drug Targets. 2005 Nov;5(7):543-9. doi: 10.2174/156800905774574066. Curr Cancer Drug Targets. 2005. PMID: 16305350 Review.

9

Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.

Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD. Brewer GJ, et al. Clin Cancer Res. 2000 Jan;6(1):1-10. Clin Cancer Res. 2000. PMID: 10656425 Clinical Trial.

10

The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.

Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD. Cox C, et al. Among authors: brewer gj. Laryngoscope. 2001 Apr;111(4 Pt 1):696-701. doi: 10.1097/00005537-200104000-00024. Laryngoscope. 2001. PMID: 11359142

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

473 results

Search Page

Filters